Overview

GEN2 Directed Cancer Immunotherapy Trial

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary & metastatic liver tumors.

Phase:

Phase 1

Details

Lead Sponsor:

GenVivo, Inc.